Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Evaluating Tumor Microenvironment Remodeling Post-TIL Therapy in Syngeneic Mouse Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Evaluating Tumor Microenvironment Remodeling Post-TIL Therapy in Syngeneic Mouse Models

Evaluating Tumor Microenvironment Remodeling Post-TIL Therapy in Syngeneic Models

CELL & GENE | RNA | BIOLOGICS

Assessing the efficacy of Tumor-Infiltrating Lymphocyte (TIL) therapies requires analysis beyond simple tumor volume measurements. A definitive evaluation hinges on quantifying how the infused cell product remodels the tumor microenvironment (TME). We utilize GxP-compliant syngeneic models to integrate multi-modal data from histology, high-parameter flow cytometry, and gene expression profiling. This approach provides a comprehensive view of immune cell infiltration, functional status, and pathway modulation, generating the robust dataset required to de-risk clinical translation and support Investigational New Drug (IND) filings.

What are the primary endpoints for evaluating TME remodeling post-TIL infusion?
Primary endpoints are multi-factorial and extend beyond tumor growth inhibition. Key readouts include quantitative changes in the composition of immune cell populations (e.g., CD8+ T cells, Tregs, MDSCs), shifts in cytokine and chemokine profiles, and modulation of immune checkpoint protein expression on both tumor and immune cells. This composite analysis provides a more accurate profile of therapeutic effect.
Why are syngeneic models preferred for these pharmacology studies?
Syngeneic models possess a fully competent and intact immune system. This is a prerequisite for studying TIL therapies, as it allows for the evaluation of complex interactions between the adoptively transferred TILs and the host’s endogenous immune cells, lymphoid tissues, and the overall TME.
How does Franklin Biolabs ensure data reproducibility in complex cell therapy studies?
Reproducibility is maintained through rigorously standardized, GxP-compliant protocols for cell handling, dosing, and tissue processing. Our bioanalytical assays are validated to ensure consistent performance. All in vivo work is conducted within our AAALAC and USDA-accredited facilities, adhering to the highest standards of animal welfare.
What advanced analytical techniques are used to characterize the TME?
We deploy a suite of advanced assays to build a comprehensive dataset. This includes multiplex immunofluorescence (mIF) for spatial analysis of immune infiltrates, high-parameter flow cytometry for deep immunophenotyping of dissociated tumors and lymphoid organs, and targeted gene expression panels to profile key immuno-oncology pathways.

Characterizing the Post-Infusion Tumor Microenvironment

The clinical success of a TIL therapy is directly linked to the persistence, trafficking, and functional activity of the infused cells within the tumor. Consequently, preclinical efficacy studies must confirm that the cell product can overcome an immunosuppressive TME. Measuring changes in tumor volume alone provides an incomplete picture of biological activity.

A robust pharmacology study focuses on characterizing the TME post-infusion. We evaluate the quantitative and qualitative shifts in immune cell populations to confirm on-target effects. This includes assessing the ratio of effector T cells to regulatory T cells and myeloid-derived suppressor cells, which is a key indicator of a restored anti-tumor immune response.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Integrating Multi-Modal Data for a Comprehensive Efficacy Profile

To build a complete mechanism-of-action profile, we integrate data from orthogonal analytical methods. This approach delivers the High-Resolution Pharmacology Validating Complex Biologicals that is necessary for advancing cell therapy programs toward the clinic. Our standard workflow combines several key analyses:

  • Histology & Multiplex Immunofluorescence: Visualizes the spatial arrangement and density of TILs, macrophages, and other immune subsets within the tumor architecture.

  • High-Parameter Flow Cytometry: Quantifies shifts in immune cell populations from dissociated tumors and secondary lymphoid organs, while simultaneously assessing cell surface markers of activation and exhaustion (e.g., PD-1, LAG-3, TIM-3).

  • Gene Expression Profiling: Measures changes in key immune signaling pathways, cytokine/chemokine expression, and metabolic programs within the TME.

Watch the full-length video on Diversifying the Value Chain

Translational Insights from Advanced Therapeutic Platforms

The principles of validating complex biologics extend across modalities. For instance, the successful use of an AAV8 vector to lower plasma cholesterol in a humanized model (PMID: 22985273) reinforces the strategic value of selecting preclinical models that faithfully recapitulate human disease biology to generate predictive data. This principle is directly applicable to selecting the correct syngeneic tumor model to test a TIL therapy.

Similarly, a study demonstrating the efficacy of an LNP-mRNA therapy for a metabolic disease (PMID: 39001827) highlights the power of developing mutation-independent platforms. The strategic insight for cell therapy is the focus on robust delivery and payload technologies that can be broadly applied to enhance TIL function or persistence, independent of the specific tumor antigen.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

GxP-Compliant Framework for IND-Enabling Studies

Our pharmacology and efficacy studies are conducted within a >100,000 sq ft facility designed to support programs from discovery through IND submission. We operate on an 18-24 month IND timeline, leveraging validated platforms to generate decision-making data efficiently. This operational excellence has contributed to a 100% IND-enabling package success rate for programs initiated since 2019 (the Franklin Biolabs brand launched in 2024).

We rigorously apply the 3Rs (Replacement, Reduction, and Refinement) principles across all in vivo studies, ensuring the highest ethical standards and data quality.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities